None listed
Conditions
Interventions
None listed
Sponsors
Dunsan Korean Medicine Hospital of Daejeon University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Men and women aged 45 to under 85 2. A person diagnosed with major or mild neurocognitive impairment based on Diagnostic and Statistical Manual of Mental Disorders-5 criteria 3. When Clinical Dementia Rating is 0.5 and corresponds to Global Deterioration Scale 2-5 4. Those who have 22 or less Korean Version of Montreal Cognitive Assessment points 5. A person who can understand the questionnaire directly or through his or her next of kin 6. A person who voluntarily agreed to a clinical research agreement by the subject or his or her legal representative
Exclusion criteria
Exclusion criteria: 1. If there are cranial lesions, brain damage, or mental retardation that may impair cognitive function. 2. Have a history of brain diseases such as Huntington's disease, normal hydrocephalus, or brain tumor 3. Have gastrointestinal, endocrine and cardiovascular diseases that are not controlled by diet or medication 4. Diabetics who are not controlled by hypoglycemic agents or who have diabetes not controlled by insulin, etc. 5. If you have severe liver disease or kidney disease enough to receive kidney dialysis 6. Anemia, hypothyroidism, vitamin deficiency, malignant disease 7. In severely unstable medical conditions (based on the results of clinical laboratory tests, Electrocardiogram, Chest X-ray, vital signs, etc.) 8. Have a history of major psychiatric disorders diagnosed by Diagnostic and Statistical Manual of Mental Disorders-5, for example, schizophrenia, delusional disorder, depressive disorder, bipolar disorder, alcohol or substance use disorder 9. Have experience in other clinical trials with intervention in the last 4 weeks 10. Females of childbearing age 11. If you do not understand the consent form or have difficulty researching due to mental retardation, emotional or intellectual problems 12. Difficulties due to blindness, hearing loss or severe speech disorder 13. If you are not eligible to participate in this clinical study at the discretion of the researcher.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Seoul Neuropsychological Screening Battery | — |
Secondary
| Measure | Time frame |
|---|---|
| Korean Version of Montreal Cognitive Assessment;Neuropsychiatric Inventory–Questionnaire;EuroQol-5 dimension;Pattern Identifications Tool for Cognitive Disorders;Body Mass Index;Integrative Medicine Patient Satisfaction Scale;Electroencephalography | — |
Countries
Korea, Republic of
Contacts
Public ContactJiyoon Lee
Dunsan Korean Medicine Hospital of Daejeon University
Outcome results
None listed